[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"spect-ct\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:spect-ct":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100620108","preliminary-evaluation-of-clinical-application-of-spect-imaging-targeting-gpc3-100620108",false,"NCT07353333","Preliminary Evaluation of Clinical Application of SPECT Imaging Targeting GPC3","Inclusion Criteria:\n\n1. the subject or his\u002Fher legal representative can sign and date the informed consent form\n2. commitment to follow the research procedures and cooperate in the implementation of the full-process research\n3. patients with high clinical suspicion or histopathology diagnosis of HCC and generally in good condition\n4. patients with a history of hepatocellular carcinoma who recur after treatment\n5. women in their reproductive years were using contraception for at least one month before screening and were committed to using contraception throughout the study period and for the prescribed period after the end of the study\n\nExclusion Criteria:\n\n1. inability to complete SPECTCT examination (including inability to lie down, claustrophobia, radiophobia, etc.)\n2. acute systemic diseases and electrolyte disorders\n3. patients with known hypersensitivity to GPC3 imaging agents or synthetic excipients\n4. patients considered by the investigator to have poor adherence\n5. pregnant or lactating patients\n6. Have other factors not suitable to participate in this test","ALL","18 Years","80 Years",{"count":19,"type":20},6,"ESTIMATED","INTERVENTIONAL",[23],"NA","This project will target patients with highly clinically suspected or histopathology diagnosed hepatocellular carcinoma (HCC) using targeted GPC3-specific imaging agents (e.g. , Iodine-131-aGPC3-Scfv) for integrated SPECTCT imaging, to evaluate the pharmacokinetics distribution of the targeted drug in patients with hepatocellular carcinoma (HCC) by low-dose integrated diagnosis and treatment (i.e. , Iodine-131-RRB- imaging, to determine the metabolism, safety and tolerability of the drug in vivo Secondary objective: to evaluate the targeting of GPC3-SPECIFIC imaging agents in patients with hepatocellular carcinoma to assess the feasibility of this targeted agent for future treatment.",[26,27],"HCC","SPECT-CT","NOT_YET_RECRUITING","2026-01-19",{"date":31,"type":32},"2026-01-20","ACTUAL",{"date":34,"type":20},"2026-01-30",{"date":36,"type":20},"2026-12-30",{"name":38,"class":39},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":4},"100601724","a-study-on-the-diagnostic-value-of-99mtc-fapi-quantitative-spectct-imaging-in-adult-solitary-bone-lesions-100601724","NCT07114211","A Study on the Diagnostic Value of 99mTc-FAPI Quantitative SPECT\u002FCT Imaging in Adult Solitary Bone Lesions","A Real-world Observational Study on the Diagnostic Value of 99mTc-FAPI Quantitative SPECT\u002FCT Imaging in Adult Solitary Bone Lesions","Inclusion Criteria:\n\n* Benign solitary bone lesions in adults (fibrous cortical defects, fibrous hyperplasia, non-ossifying fibroma, osteoblastoma, osteoid osteoma, osteochondroma, etc.); Malignant solitary bone lesions in adults (osteosarcoma, Ewing's sarcoma, chondrosarcoma, malignant giant cell tumour of bone, etc.); Other fibroblast-rich bone lesions (chordoma, alveolar soft part sarcoma, fibrosarcoma, malignant fibrous histiocytoma, etc.).\n\nExclusion Criteria:\n\n* Severe liver and kidney dysfunction; Pregnant women and breastfeeding patients; Patients in poor physical condition who cannot tolerate the examination; Patients who cannot cooperate to complete the examination; Patients under the age of 18.",{"count":49,"type":20},50,[23],"Using the novel FAPI probe 99mTc-HYNIC-FAPI-04 and quantitative SPECT\u002FCT imaging technology, this study investigates the diagnostic efficacy of 99mTc-HYNIC-FAPI-04 quantitative SPECT\u002FCT in patients with common solitary bone lesions in adults, and compares its diagnostic performance with conventional CT, MRI, and 99mTc-MDP bone scintigraphy. Follow-up pathological results of patients post-surgery were analysed to assess the accuracy of 99mTc-HYNIC-FAPI-04 diagnostic outcomes, and its diagnostic value and significance were evaluated.",[53,27],"Bone Lesion","2025-08-04",{"date":56,"type":32},"2025-08-11",{"date":58,"type":20},"2025-08-15",{"date":60,"type":20},"2028-06-01",{"name":62,"class":39},"Xijing Hospital"]